Endpoints News2d
FDA ap­proves Sanofi's RNAi drug for he­mo­phil­ia A and B
FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...